Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of etirinotecan pegol versus physician's choice chemotherapy in metastatic breast cancer with stable brain metastases
2016-002453-38Phase 3Completed
- Sponsor
- Nektar Therapeutics
- Start
- Nov 2016
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of etirinotecan pegol in breast cancer and brain metastases (2 arms), sponsored by Nektar Therapeutics. Primary endpoint: Overall survival. Started Nov 2016; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on 2016-002453-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002453-38.